Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

• ClinicalTrials.gov Identifier: NCT05782179
• Recruitment Status: Active, not recruiting
• First Posted: March 23, 2023
• Last Update Posted: March 28, 2024
• Sponsor: Minervax ApS
• Collaborator: Iqvia Pty Ltd
• Information provided by (Responsible Party): Minervax ApS

Study Description

Brief Summary:

The study is a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and immunogenicity of three doses of GBS NN/NN2 with Alhydrogel® (Recombinant protein vaccine against Group B Streptococcus) in elderly participants aged 55 to 75.Participants will be followed up to 6 months after last vaccination.

Condition or disease	Intervention/treatment	Phase
Group B Streptococcal Infections	Biological: GBS-NN/NN2; Biological: Placebo	Phase 1

Detailed Description:

Sixty (60) healthy older adult participants aged 55 to 75 years will be randomised in two cohorts; 30 obese and/or diabetic participants aged 55 to 75 years will be randomised in two cohorts.

Participants will be involved in the study for approximately one year including screening and safety follow-up.

Eligible participants will be administered a dose of GBS-NN/NN2 or placebo on three occasions: the first dose will be administered on Day 1, followed by the second and third doses 4 and 24 weeks later, respectively.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 90 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Prevention
• Official Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of Group B Streptococcus Vaccine (GBS NN/NN2 With Alhydrogel®) in Elderly Participants Aged 55 to 75
• Actual Study Start Date: March 1, 2023
• Actual Primary Completion Date: December 14, 2023
• Estimated Study Completion Date: May 16, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort 1 - Active; Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).	Biological: GBS-NN/NN2; GBS-NN/NN2 bound to alhydrogel as an adjuvant
Placebo Comparator: Cohort 1 - Placebo; Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).	Biological: Placebo; Normal Saline 0.9 %
Experimental: Cohort 2 - Active; Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).	Biological: GBS-NN/NN2; GBS-NN/NN2 bound to alhydrogel as an adjuvant
Placebo Comparator: Cohort 2 - Placebo; Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).	Biological: Placebo; Normal Saline 0.9 %
Experimental: Cohort 3 - Active; Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).	Biological: GBS-NN/NN2; GBS-NN/NN2 bound to alhydrogel as an adjuvant
Placebo Comparator: Cohort 3 - Placebo; Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).	Biological: Placebo; Normal Saline 0.9 %
Experimental: Cohort 4 - Active; Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).	Biological: GBS-NN/NN2; GBS-NN/NN2 bound to alhydrogel as an adjuvant
Placebo Comparator: Cohort 4 - Placebo; Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).	Biological: Placebo; Normal Saline 0.9 %

Outcome Measures

Primary Outcome Measures :

1. Safety and tolerability of GBS-NN/NN2 vaccine [ Time Frame: Up to 28 days after each vaccination ]
   • Safety and tolerability as determined by the occurrence of AEs consisting of local and systemic reactogenicity within 7 days after vaccination
   • Unsolicited AEs, including AESIs, MAAEs and SAEs within 28 days after each vaccination
   • AESIs, MAAEs, ARs/SARs leading to withdrawal from the study.

Secondary Outcome Measures :

1. To evaluate IgG antibody response to the GBS-NN/NN2 vaccine at Day 197 [ Time Frame: Day 197 ]
   Geometric mean antibody concentration in μg/mL for antibodies to the four individual Alps
2. To evaluate IgG antibody responses induced by the three vaccine doses, on a 0-, 1- and 6-month regimen, in older adult participants 4 weeks after each vaccination. [ Time Frame: 4 weeks after each vaccination ]
   Geometric mean fold increase in antibody concentration for antibodies to the four individual Alps
3. To assess whether pre existing antibody levels affect the vaccine-induced antibody response. [ Time Frame: Up to 6 months after last vaccination ]
   Seroconversion rate (proportion of participants with a 4-fold increase above baseline - pre dose concentration) at any time post vaccination.
4. To evaluate the immune response up to 6 months following the third dose [ Time Frame: Up to day 197 ]
   Proportion of participants achieving antibody concentrations for antibodies to the four individual Alps (Alp 1, Alp2/3, Rib and AlpC) above specific thresholds at Days 29, 57, 169, and 197
5. To evaluate the long-term safety profile of the GBS-NN/NN2 vaccine between Day 57 (28 days post second injection) to Day 168 and 6 months following the third dose (safety endpoint) [ Time Frame: Up to day 365 ]
   • Proportion of participants with any SAE from between Day 57 (28 days post second injection) to Day 168 and 28 days after third vaccination (Day 197) up to Day 365.
   • Proportion of participants with MAAEs, AESIs, ARs/SARs requiring a medical consultation, and or leading to withdrawal from the study from 28 days after third vaccination (Day 197) up to Day 365.

Eligibility Criteria

• Ages Eligible for Study: 55 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Participants aged 55 to 75 years.
2. Body mass index (BMI) ≥18 and ≤30 kg/m2 for healthy participants, ≥ 30 to ≤45 kg/m2 for obese participants and ≥18 to ≤45 kg/m2 for type 2 diabetic participants.
3. Able to voluntarily provide written informed consent to participate in the study.
4. Female participants must be post-menopausal.
5. Participants capable and willing to follow trial schedule and procedures.

Exclusion Criteria:

1. Participants who have received a GBS vaccine previously.

2. Participants with history or presence of significant (as evaluated by the investigator) cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, psychiatric, autoimmune disease or current infection.

   NOTE: Patients with type 2 diabetes are to be recruited for Cohort 3 and Cohort 4.

3. Laboratory values at screening which are deemed by the investigator to be clinically significantly abnormal.
4. Current or history of drug or alcohol abuse per investigator judgement.
5. Positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
6. Participants currently participating in a clinical trial.
7. Participants receiving an investigational drug, vaccine or device during the 90 days preceding the initial dose in this study.
8. Any significant illness during the 4 weeks preceding the vaccination visit, per investigator judgement.
9. Participants with a history of severe allergic reactions after previous vaccination.

10. Participants who have received any vaccine within 30 days of first IMP administration, or who are planning to receive any vaccine (eg, travel vaccines) up to 30 days after each vaccination.

    NOTE: Exceptions could be made for emergency vaccinations (eg, tetanus) or vaccination campaigns (eg, SARS, CoV-2 or influenza) which will be permitted not less than 7 days before or after study vaccination.

11. Participants receiving immunosuppressive therapy or immunoglobulins in the 6 months prior to screening.
12. Participants within a 7-day period after an acute infection in the 7 days preceding vaccination, as per investigator judgement, or with fever (oral temperature >37.9°C) in the 72 hours preceding vaccination.
13. Participants who have received antipyretics/analgesics treatment within 72 hours prior to dosing.

14. Participants on chronic medications that are likely to affect the assessments specified in the protocol (eg, anticoagulant therapy, systemic steroids).

    NOTE: Chronic medications such as antihypertensives, bronchodilators, statins that do not affect the immune system, will be permitted and allowed to continue during the study at the discretion of the investigator. Treatment for diabetes will be continued as required for the diabetic participants recruited. Non-steroidal anti-inflammatory drugs or paracetamol will be permitted for the treatment of headache or other symptoms during the study. Use of over the counter (OTC) vitamins and dietary supplements is allowed.

15. Participants with skin defects and/or tattoos at the proposed site of vaccine administration.
16. Donation of blood or blood products within 90 days prior to first study vaccination.
17. Participants who, in the opinion of the Investigator, are unsuitable for participation in the study.
18. Involvement in the planning and/or conduct of the study (applies to both Sponsor personnel and/or personnel at the study centre or Clinical Research Organisation [CRO]).

Contacts and Locations

Locations

Belgium

University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) department

Ghent, Belgium, 9000

Sponsors and Collaborators

Minervax ApS

Iqvia Pty Ltd

Investigators

• Study Director: Geoff Kitson; gkitson@propharmapartners.uk.com

More Information

• Responsible Party: Minervax ApS
• ClinicalTrials.gov Identifier: NCT05782179
• Other Study ID Numbers: MVX0006; 2022-003681-20 ( EudraCT Number )
• First Posted: March 23, 2023
• Last Update Posted: March 28, 2024
• Last Verified: March 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections